The Long Goodbye: Lilly Finally Kicks Troubled Sepsis Drug Xigris To The Curb
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly & Co. announced Oct. 25 that it is ending its ten-year relationship with Xigris, withdrawing the sepsis drug from all markets and ceasing further clinical trials.